PRNewsWire
24 Aug 2026, 11:50 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The THERMAC breast cancer trial has advanced to Phase III specifically focusing on IceCure's cryoablation after it achieved the highest complete ablation rate among evaluated technologies. — Advancement to Phase III based on superior performance data is a major clinical milestone that significantly increases the probability of regulatory success and market adoption.
+0.60IceCure has entered into an exclusive distribution agreement with Scovas Medical to commercialize ProSense® systems in the Netherlands. — Expanding the commercial footprint via an experienced local distributor provides a clear path to revenue growth in a strategic European market.
+0.30Previously published THERMAC data for ProSense® showed a 94% success rate, 0% complication rate, and 100% treatment tolerance without general anesthesia. — Strong safety and efficacy metrics provide a competitive advantage and support the value proposition for physician adoption.
+0.30Continue reading
6 related stories
Search tags
Which stocks this story touches
The company signed an exclusive distribution agreement in the Netherlands and reported high success rates in clinical trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
